HOME > ARCHIVE
ARCHIVE
- RESEARCH &DEVELOPMENT NEWS IN BRIEF
June 9, 2003
- Sumitomo Pharm: Sales, Profits Decline on Sluggish Sales of Major Products
June 9, 2003
- MEDICAL DEVICE NEWS IN BRIEF
June 9, 2003
- Tsumura: Ethical Kampo Products Drive Growth in Sales, Profits
June 9, 2003
- DIAGNOSTIC NEWS IN BRIEF
June 9, 2003
- Kaken: Sales Flat but Operating Profits Up 2.9%
June 9, 2003
- Rohto: Eye, Skin Care Businesses Drive 4.7% Sales Increase
June 9, 2003
- Nikken: 12.7% Drop in Sales due to Theodur Shortage
June 9, 2003
- Fuso: Weaker Sales of Kindaly, Generic Competition Hit Sales, Profits
June 9, 2003
- Nippon Shinyaku: Cost-cutting Helps Boost Operating Profits
June 9, 2003
- Toyama Chemical: Sales Up 16.4% Despite Slump of Major Products
June 9, 2003
- Wakamoto: Ethical Eye Drops Boost Sales, Profits
June 9, 2003
- Nippon Chemiphar: Uralyt Contributes to Growth in Sales
June 9, 2003
- Meiji Seika Kaisha: Downturn in Sales, Profits Reported
June 9, 2003
- Fukujin: 14.6% Growth in Sales, 71.0% Increase in Net Profits
June 9, 2003
- Matsumotokiyoshi: 20.1% Rise in Operating Profits to \13.5 Billion
June 9, 2003
- Azwell: Cost-cutting, Better Productivity Boost Sales, Profits
June 9, 2003
- NHI Pricing System Should Assess Technical Innovation: Mr Nagayama of JPMA
June 9, 2003
- Yamanouchi: Record Sales Boost Domestic Share to 5%
June 2, 2003
- Fukujin Wants to Become No. 1 Drug Wholesaler by Merging with Azwell
June 2, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
